Man, did that year go fast!
It seems like it was only 2 months ago that Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) and Xdemvy (lotilaner ophthalmic solution 0.25%, Tarsus Pharmaceuticals) were approved by the FDA and entered the market. It was the second half of 2023, of course, when they made their debut. It is truly amazing how quickly both medications have become fixtures in the daily strategies of literally thousands of eye doctors treating dry eye disease (DED). Not only that, Miebo and Xdemvy, along with Lacrifill (Nordic (Read more...)